Merit Med Sys Inc Stock Price, News & Analysis

Merit Medical Systems (MMSI) reported Q1 2023 revenue of $297.6 million, marking an 8.0% increase from Q1 2022. Constant currency revenue grew 9.8% year-over-year, driven by performance in U.S. and international markets. The GAAP operating margin improved to 8.9% compared to 5.5% in Q1 2022, while non-GAAP operating margin rose to 16.1%. Q1 GAAP EPS was $0.36, up from $0.18 the previous year. CEO Fred Lampropoulos highlighted the strong start to FY 2023, updating financial guidance with projected revenue between $1.217 billion and $1.229 billion. Positive outlook includes expectations of 5%-6% growth in the cardiovascular segment and earnings per share of $1.71 to $1.79 by year-end. Cash and equivalents stood at $57.9 million, with total debt obligations of $197.8 million.

Merit Medical Systems, Inc. (NASDAQ: MMSI) has announced it will release its financial results for the quarter ended March 31, 2023, after the market closes on April 26, 2023. Following the release, the company will host an investor conference call at 5:00 p.m. Eastern Time the same day. Participants can pre-register for the call through a provided link, receiving confirmation with dial-in details. Additionally, a live webcast will be accessible via another link. Merit Medical, founded in 1987, is a prominent global manufacturer and marketer of healthcare technology, employing approximately 7,100 individuals worldwide, with operations in various countries, including the U.S., Europe, and Asia.

Merit Medical Systems has expanded its SwiftNINJA Steerable Microcatheter line with new low-profile 2.4F distal diameter options and longer lengths of 125 cm and 150 cm. The microcatheter provides a 180-degree articulation designed for easier access to challenging vascular areas without a guide wire, potentially reducing procedure time and radiation exposure. The SwiftNINJA stands out as the only widely available steerable microcatheter in the U.S., allowing greater versatility in complex procedures. Founded in 1987, Merit develops and markets devices used in various medical fields, employing over 7,100 individuals globally.

Merit Medical Systems (NASDAQ: MMSI) reported Q4 2022 revenue of $293.4 million, a 5.4% increase from Q4 2021. Constant currency organic revenue rose 8.2%. The GAAP operating margin improved to 10.4% from 7.9%, while non-GAAP operating margin increased to 17.8%. GAAP EPS was $0.58, up from $0.36, and non-GAAP EPS reached $0.79, compared to $0.71. The company anticipates 2023 revenue of $1.194-$1.210 billion, projecting a 4%-5% growth year-on-year. Merit ended 2022 with $58.4 million in cash and cash equivalents and $198.2 million in total debt.

Merit Medical Systems has received FDA Breakthrough Device Designation for its SCOUT MD Surgical Guidance System, enhancing surgical precision for breast and soft tissue cancer treatments. This innovative system allows the implantation of up to four unique reflector configurations, improving tumor localization and minimizing damage to healthy tissue, thereby reducing the need for repeat surgeries. With breast cancer being the most common cancer globally, representing 12.5% of new cases, the SCOUT MD aims to optimize surgical outcomes and patient care. Merit commits to advancing oncology technologies, enhancing patient experiences in cancer treatment.

Merit Medical Systems, Inc. (NASDAQ: MMSI) has announced that it will release its financial results for the fourth quarter and full year of 2022 on February 22, 2023, following the market close. Alongside this, the company will provide guidance for fiscal year 2023. An investor conference call is scheduled for the same day at 5:00 p.m. Eastern time.

Merit is known for its healthcare technology solutions, serving hospitals globally with a dedicated workforce of over 7,100 employees across various locations, including the U.S. and several countries in Europe, Asia, and South America.

Merit Medical Systems (NASDAQ: MMSI) has successfully enrolled its first patient in a new observational study of EmboCube Embolization Gelatin, a product designed to control bleeding during trauma. This minimally-invasive embolization technique is crucial as uncontrolled bleeding is a leading cause of preventable death globally. The EmboCube, which offers uniformly pre-cut gelatin foam for efficient delivery, is currently approved in Europe and Canada but not yet in Australia. The study aims to enroll 100 patients across Australia and France.